These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25287587)

  • 21. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses.
    Liu W; Wong YC; Chen SMY; Tang J; Wang H; Cheung AKL; Chen Z
    Vaccine; 2018 Jul; 36(31):4621-4632. PubMed ID: 29961605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Immunogen Selectively Eliciting CD8
    Ishii H; Terahara K; Nomura T; Takeda A; Okazaki M; Yamamoto H; Tokusumi T; Shu T; Matano T
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32024773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take? Could a CD8
    McMichael AJ
    Cold Spring Harb Perspect Biol; 2018 Sep; 10(9):. PubMed ID: 29254977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus antibodies and the vaccine problem.
    Chiodi F; Weiss RA
    J Intern Med; 2014 May; 275(5):444-55. PubMed ID: 24581142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
    Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.
    Santra S; Liao HX; Zhang R; Muldoon M; Watson S; Fischer W; Theiler J; Szinger J; Balachandran H; Buzby A; Quinn D; Parks RJ; Tsao CY; Carville A; Mansfield KG; Pavlakis GN; Felber BK; Haynes BF; Korber BT; Letvin NL
    Nat Med; 2010 Mar; 16(3):324-8. PubMed ID: 20173754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HIV-1 vaccine race.
    Ho DD; Huang Y
    Cell; 2002 Jul; 110(2):135-8. PubMed ID: 12150921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
    Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
    J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
    Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
    J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
    Sheppard N; Sattentau Q
    Expert Rev Mol Med; 2005 Feb; 7(2):1-21. PubMed ID: 15710051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing optimal HIV-vaccine T-cell responses.
    Streeck H
    Curr Opin HIV AIDS; 2016 Nov; 11(6):593-600. PubMed ID: 27559707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
    Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
    PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
    Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
    J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.
    Fouts TR; Bagley K; Prado IJ; Bobb KL; Schwartz JA; Xu R; Zagursky RJ; Egan MA; Eldridge JH; LaBranche CC; Montefiori DC; Le Buanec H; Zagury D; Pal R; Pavlakis GN; Felber BK; Franchini G; Gordon S; Vaccari M; Lewis GK; DeVico AL; Gallo RC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E992-9. PubMed ID: 25681373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.